$20m wheeze gives MediciNova breathing room for FDA and partnering
This article was originally published in Scrip
Executive Summary
MediciNova entered into a common stock purchase agreement with Aspire Capital Fund that gives it access to $20 million over the next two years as the San Diego-based biopharma company prepares to tell the US FDA at a 22 October end-of-Phase II meeting why its acute asthma drug MN-221 (bedoradrine) should be tested in a Phase III clinical trial.